Q-Line Biotech Limited (NSE:QLINE)

India · Delayed Price · Currency is INR

516.55

-10.25 (-1.95%)

At close: Nov 9, 2026

Market Cap	12.05B
Revenue (ttm)	3.42B +12.3%
Net Income	567.13M +1.3%
EPS	35.41 -3.5%
Shares Out	23.33M
PE Ratio	14.59
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,200
Open	535.00
Previous Close	526.80
Day's Range	513.50 - 540.00
52-Week Range	431.00 - 735.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2026

About Q-Line Biotech

Q-Line Biotech Limited develops, manufactures, and markets various reagents and consumables in India and internationally. It offers reagents and diagnostic kits, analysers, point-of-care devices, molecular diagnostics for applications in immunodiagnostics, hematology, molecular diagnostics, clinical chemistry, and others, as well as in vitro testing of human samples, supporting disease prediction, prevention, diagnosis, monitoring, and health status evaluation. The company also provides diagnostic equipment comprising analyzers, point-of-care d... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances

Founded 2010

Employees 357

Stock Exchange National Stock Exchange of India

Ticker Symbol QLINE

Full Company Profile

Financial Performance

In fiscal year 2026, Q-Line Biotech's revenue was 3.42 billion, an increase of 9.13% compared to the previous year's 3.13 billion. Earnings were 567.13 million, an increase of 56.75%.

Financial Statements